In This Article:
In a week marked by a flurry of earnings reports and mixed economic signals, global markets have shown some volatility, with major U.S. indexes like the Nasdaq Composite and S&P MidCap 400 reaching record highs before retreating. Amidst this backdrop, growth stocks have generally underperformed compared to value shares, highlighting the importance of identifying companies with strong fundamentals and high insider ownership as potential indicators of confidence in future performance.
Top 10 Growth Companies With High Insider Ownership
Name | Insider Ownership | Earnings Growth |
Archean Chemical Industries (NSEI:ACI) | 22.9% | 34% |
Kirloskar Pneumatic (BSE:505283) | 30.3% | 26.3% |
People & Technology (KOSDAQ:A137400) | 16.4% | 35.6% |
Laopu Gold (SEHK:6181) | 36.4% | 33% |
Medley (TSE:4480) | 34% | 30.4% |
Seojin SystemLtd (KOSDAQ:A178320) | 30.7% | 49.1% |
Findi (ASX:FND) | 34.8% | 64.8% |
Adveritas (ASX:AV1) | 21.2% | 144.2% |
Plenti Group (ASX:PLT) | 12.8% | 107.6% |
UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
Let's uncover some gems from our specialized screener.
Mrs. Bectors Food Specialities
Simply Wall St Growth Rating: ★★★★★☆
Overview: Mrs. Bectors Food Specialities Limited manufactures and distributes various food products in India, with a market cap of ?110.75 billion.
Operations: The company generates revenue of ?16.89 billion from its food products segment in India.
Insider Ownership: 34.7%
Mrs. Bectors Food Specialities shows potential as a growth company with high insider ownership, despite recent shareholder dilution through a follow-on equity offering of INR 4 billion. The company's earnings are expected to grow significantly at over 20% annually, outpacing the Indian market's average. While insider buying has surpassed selling in recent months, substantial non-cash earnings and changes in auditors may require careful monitoring by investors seeking long-term growth opportunities.
Metropolis Healthcare
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Metropolis Healthcare Limited offers diagnostic services both in India and internationally, with a market cap of ?110.18 billion.
Operations: The company's revenue is primarily derived from its Pathology Service segment, which generated ?12.44 billion.
Insider Ownership: 18.8%
Metropolis Healthcare's earnings are forecast to grow significantly at 23.1% annually, surpassing the Indian market average. However, notable insider selling has occurred recently without substantial insider buying, which might concern some investors. Recent executive changes include a new Chief Information Officer and the resignation of the CFO. The company aims for 13-15% revenue growth in 2025, driven by volume increases and product mix enhancements to boost revenue per patient.